TransCelerate BioPharma aims to solve common drug development challenges
Ten leading European and US drug companies have formed a non-profit organisation to accelerate the development of new medicines.
Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Roche and Sanofi have established TransCelerate BioPharma, said to be the largest initiative of its kind, with the aim of improving the quality of clinical studies and bringing new medicines to patients faster.
Each company will combine financial and other resources, including personnel, to solve industry-wide problems. They have agreed to specific outcome-oriented objectives and have established guidelines for sharing information and expertise to advance collaboration.
Newly appointed acting ceo of TransCelerate BioPharma , Garry Neil, a partner at Apple Tree Partners and formerly corporate vp of science and technology at Johnson & Johnson, said: ‘There is a critical need to increase substantially the number of innovative new medicines, while eliminating inefficiencies that drive up r&d costs.’
‘Our mission at TransCelerate BioPharma is to work together across the global research and development community and share research and solutions that will simplify and accelerate the delivery of exciting new medicines for patients.’
TransCelerate members will initially look at the execution of clinical trials and have selected five projects for funding and development, including: developing a standard methodology for collecting data from patient tests, mutual recognition of study site qualification and training, developing a risk-based site monitoring approach and standards, developing clinical data standards, and establishing a comparator drug supply model.
TransCelerate will also collaborate with several industry groups, as well as government regulators including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), and contract research organisations.
Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, said the collaboration has the promise ‘to strengthen the industry and its ability to develop innovative and much-needed therapies for patients’.